Lung Cancer
Hsu HS, Chen TP, Hung CH, Wen CK, Lin RK, Lee HC, Wang YC.
Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Cancer. 2007 Nov 1;110(9):2019-26.
Tsou JA, Galler JS, Siegmund KD, Laird PW, Turla S, Cozen W, Hagen JA, Koss MN, Laird-Offringa IA.
Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma.
Mol Cancer. 2007 Oct 29;6:70.
Belinsky SA, Grimes MJ, Casas E, Stidley CA, Franklin WA, Bocklage TJ, Johnson DH, Schiller JH.
Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum.
Br J Cancer. 2007 Apr 23;96(8):1278-83.
Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, Zheng Y, Feng Z, Hol B, Prinsen C, Thunnissen FB, Gazdar AF.
Application of a methylation gene panel by quantitative PCR for lung cancers.
Cancer Lett. 2007 Mar 8;247(1):56-71
Additional References
Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y, Franklin WA, Herman JG, Baylin SB, Bunn PA, Byers T.
Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort.
Cancer Res. 2006;66(6):3338-44.
Schmiemann V, Bocking A, Kazimirek M, Onofre AS, Gabbert HE, Kappes R, Gerharz CD, Grote HJ.
Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study.
Clin Cancer Res. 2005;11(21):7728-34.
Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, Crowell RE, Karp DD,
Stidley CA, Picchi MA
Gene promoter methylation in plasma and sputum increases with lung cancer risk.
Clin Cancer Res. 2005;11(18):6505-11.
Divine KK, Pulling LC, Marron-Terada PG, Liechty KC, Kang T, Schwartz AG, Bocklage TJ, Coons TA, Gilliland FD, Belinsky SA.
Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers.
Int J Cancer. 2005;114(3):400-5
Bowman RV, Yang IA, Semmler AB, Fong KM.
Epigenetics of lung cancer.
Respirology. 2006;11(4):355-65.
Machida EO, Brock MV, Hooker CM, Nakayama J, Ishida A, Amano J, Picchi MA, Belinsky SA, Herman JG, Taniguchi S, Baylin SB.
Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer.
Cancer Res. 2006;66(12):6210-8.
Nakata S, Sugio K, Uramoto H, Oyama T, Hanagiri T, Morita M, Yasumoto K.
The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Cancer. 2006;106(10):2190-9.
Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH.
Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
Cancer Res. 2006;66(8):4049-54.
Grote HJ, Schmiemann V, Geddert H, Bocking A, Kappes R, Gabbert HE, Sarbia M.
Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
Cancer. 2006;108(2):129-34.
Toyooka S, Tokumo M, Shigematsu H, Matsuo K, Asano H, Tomii K, Ichihara S, Suzuki M, Aoe M, Date H, Gazdar AF, Shimizu N.
Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers.
Cancer Res. 2006;66(3):1371-5.
Kim YT, Park SJ, Lee SH, Kang HJ, Hahn S, Kang CH, Sung SW, Kim JH.
Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung.
J Thorac Cardiovasc Surg. 2005;130(5):1378.
de Fraipont F, Moro-Sibilot D, Michelland S, Brambilla E, Brambilla C, Favrot MC
Promoter methylation of genes in bronchial lavages: A marker for early diagnosis of primary and relapsing non-small cell lung cancer?
Lung Cancer. 2005;50(2):199-209.
Cirincione R, Lintas C, Conte D, Mariani L, Roz L, Vignola AM, Pastorino U, Sozzi G.
Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: A nested case-control study.
Int J Cancer. 2005 Sep 8; [Epub ahead of print]
Olaussen KA, Soria JC, Park YW, Kim HJ, Kim SH, Ro JY, Andre F, Jang SJ.
Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC.
Eur J Cancer. 2005;41(14):2112-9.
Safar AM, Spencer H 3rd, Su X, Coffey M, Cooney CA, Ratnasinghe LD, Hutchins LF, Fan CY.
Methylation profiling of archived non-small cell lung cancer: a promising prognostic system.
Clin Cancer Res. 2005;11(12):4400-5.
Russo AL, Thiagalingam A, Pan H, Califano J, Cheng KH, Ponte JF, Chinnappan D, Nemani P, Sidransky D, Thiagalingam S.
Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer.
Clin Cancer Res. 2005;11(7):2466-70.
Suzuki M, Hao C, Takahashi T, Shigematsu H, Shivapurkar N, Sathyanarayana UG, Iizasa T, Fujisawa T, Hiroshima K, Gazdar AF.
Aberrant methylation of SPARC in human lung cancers.
Br J Cancer. 2005;92(5):942-8.
Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, Kozuki T, Aoe M, Kiura K, Ueoka H, Tanimoto M.
Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.
Clin Cancer Res. 2005;11(3):1219-25.
Tsou JA, Shen LY, Siegmund KD, Long TI, Laird PW, Seneviratne CK, Koss MN, Pass HI, Hagen JA, Laird-Offringa IA.
Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung.
Lung Cancer.2005;47(2):193-204.
Divine KK, Pulling LC, Marron-Terada PG, Liechty KC, Kang T, Schwartz AG, Bocklage TJ, Coons TA, Gilliland FD, Belinsky SA.
Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers.
Int J Cancer. 2005;114(3):400-5
Irimia M, Fraga MF, Sanchez-Cespedes M, Esteller M.
CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer.
Oncogene. 2004;23(53):8695-9.
Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, Yang SC, Han Y, Baylin SB, Herman JG, Brock MV.
Hypermethylation of the GATA genes in lung cancer.
Clin Cancer Res. 2004;10(23):7917-24.
Belinsky SA.
Gene-promoter hypermethylation as a biomarker in lung cancer.
Nat Rev Cancer. 2004;4(9):707-17. Review.
Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, Hong WK, Mao L.
Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
Clin Cancer Res. 2004;10(18 Pt 1):6119-25.
Hanabata T, Tsukuda K, Toyooka S, Yano M, Aoe M, Nagahiro I, Sano Y, Date H, Shimizu N.
DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers.
Oncol Rep. 2004;12(1):177-80.
Kim H, Kwon YM, Kim JS, Lee H, Park JH, Shim YM, Han J, Park J, Kim DH.
Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
J Clin Oncol. 2004;22(12):2363-70.
Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA.
DNA methylation analysis: a powerful new tool for lung cancer diagnosis.
Oncogene 2002;21(35):5450-61
Zöchbauer-Müller S, Minna JD, Gazdar AF.
Aberrant DNA methylation in lung cancer: biological and clinical implications.
Oncologist 2002;7(5):451-7
Zöchbauer-Müller S, Fong KM, Virmane AK, Geradts J, Gazdar AF, Minna JD.
Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
Cancer Res. 2001;61(1):249-55.
Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA.
Predicting lung cancer by detecting aberrant promoter methylation in sputum.
Cancer Res. 2000;60(21):5954-8.
Sanchez-Cespedes M, Reed AL, Buta M, Wu L, Westra WH, Herman JG, Yang SC, Jen J, Sidransky D.
Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
Oncogene 1999;18(43):5843-9.